- Lantern will leverage its proprietary AI platform, RADR®, to
rapidly develop novel cryptophycin-antibody drug conjugates (ADCs),
which represent an exciting class of potent and highly targeted
drug candidates.
- The collaboration with Bielefeld University (Germany) will be
led by Professor Norbert Sewald, Ph.D., a leading expert in the
synthesis of cryptophycins, development of ADCs, and the
coordinator of the “Magicbullet::reloaded” consortium.
- The global ADC market is currently over $4.0 billion and is
projected to reach $14.0 billion by 2027.
- Lantern is receiving an exclusive and worldwide option to
license intellectual property from Bielefeld University related to
the collaboration and IP generated from the collaboration.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced it will be leveraging its AI
platform, RADR®, in a research collaboration with Bielefeld
University (Bielefeld, Germany) to develop antibody-drug conjugates
(ADCs) with high therapeutic and antitumor potential. The
collaboration will leverage insights from Lantern’s recently
developed RADR® AI ADC module in combination with research from
Professor Norbert Sewald, Ph.D., the principal investigator for
Bielefeld and leader of Magicbullet::reloaded, a European
consortium focused on developing novel drug delivery mechanisms,
including ADCs. Outcomes from the collaboration are expected to
pave the way for next-generation ADCs and other drug conjugates
that are designed using AI and that can be developed with
potentially higher efficacy, at a faster pace, and with
significantly reduced costs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230608005298/en/
The global ADC market is currently over
$4.0 billion and is projected to reach $14.0 billion by 2027
(Graphic: Business Wire)
The initial aim of the collaboration will be to synthesize and
evaluate novel ADCs linked to cryptophycins, which are promising
antitumor molecules, in part because of their potency at ultra-low,
picomolar, concentrations. The cryptophycin-ADCs will be tested
across multiple cancer cell lines and initial results are expected
during 2023.
”We have ample experience in structure-activity relationships of
cryptophycins as well in the synthesis of ADCs and small
molecule-drug conjugates (SMDCs). Teaming up with top researchers
from European academia and industry in the consortium of
Magicbullet::reloaded further reinforced this capacity. We now look
forward to the collaboration with Lantern,” said Dr. Sewald.
“Cryptophycins are an exciting family of highly potent
heterocyclic peptides from Cyanobacteria that have demonstrated
antitumor potency and can inhibit tumor growth by strongly
interfering with microtubule stability and assembly,” stated Kishor
Bhatia, Ph.D., Lantern’s Chief Scientific Officer. “Dr. Sewald and
his group are experts in the synthesis of cryptophycin derivatives
and have established extensive groundwork to support the targeted
ADC delivery of cryptophycins. By leveraging our RADR® platform’s
AI ADC development module and partnering with Dr. Sewald, we expect
to be able to select and advance cryptophycin-ADCs towards the
clinic with better targeting and therapeutic efficacy for patients
with advanced cancers with limited therapeutic options,” continued
Dr. Bhatia.
After the initial aims of the collaboration are completed,
Lantern plans to leverage its AI ADC development module, which is
fully integrated into RADR®, to launch multiple ADCs that can
leverage cryptophycins or other promising payloads. Lantern also
expects to use the AI ADC development module with other
collaborators, both academic and commercial, to develop promising
ADC candidates for launch into targeted clinical trials.
This AI-guided strategy has the potential to de-risk the ADC
drug development process, while simultaneously enhancing the
creation of effective and targeted ADCs. The rapidly growing global
ADC market is currently valued at over $4.0 billion and is
projected to reach $14.0 billion by 2027. There are currently 12
ADCs that have been approved by the US Food and Drug Administration
(FDA) for the treatment of cancer and approximately 37 ADCs in
current late-stage oncology trials.
Under the terms of the collaboration, Dr. Sewald and his group
will synthesize, optimize, and provide initial testing of the
cryptophycin-ADCs. Lantern is also receiving an exclusive and
worldwide option to license intellectual property (IP) from
Bielefeld University related to the collaboration and IP generated
from the collaboration.
About Norbert Sewald, Ph.D.:
Dr. Sewald is a Professor of Organic and Bioorganic Chemistry at
Bielefeld University in Bielefeld, Germany. His research group’s
focus includes the development of antibody-drug and peptide-drug
conjugates, the isolation and total synthesis of natural products,
the chemical modification of bioactive peptides, and the
biocatalytic halogenation of amino acids, peptides, and proteins.
Dr. Sewald is also a lead investigator of a European consortium
called Magicbullet::reloaded, which is focused on investigating the
field of ADCs, peptide-drug conjugates, and small molecule-drug
conjugates to stimulate tumor immune responses and overcome
resistance to immunotherapy.
Dr. Sewald received his Ph.D. in Organic Chemistry from the
Technical University of Munich, Munich, Germany, and completed his
Postdoctoral research training in the lab of Prof. Sir J.E.
Baldwin, Dyson Perrins Laboratory at the University of Oxford,
Oxford, UK. He has served as a full Professor at Bielefeld
University since 1999.
About Lantern Pharma:
Lantern Pharma is an AI company transforming the cost, pace, and
timeline of oncology drug discovery and development. Our
proprietary AI and machine learning (ML) platform, RADR®, leverages
over 25 billion oncology-focused data points and a library of 200+
advanced ML algorithms to help solve billion-dollar, real-world
problems in oncology drug development. By harnessing the power of
AI and with input from world-class scientific advisors and
collaborators, we have accelerated the development of our growing
pipeline of therapies including eleven cancer indications and an
antibody-drug conjugate (ADC) program. On average, our newly
developed drug programs have been advanced from initial AI insights
to first-in-human clinical trials in 2-3 years and at approximately
$1.0-2.0 million per program.
Our lead development programs include two Phase 2 clinical
programs and multiple upcoming Phase 1 clinical trials anticipated
for 2023. We have also established a wholly-owned subsidiary,
Starlight Therapeutics Inc., to focus exclusively on the clinical
execution of our promising therapies for CNS and brain cancers,
many of which have no effective treatment options. Our AI-driven
pipeline of innovative product candidates is estimated to have a
combined annual market potential of over $15 billion USD and have
the potential to provide life-changing therapies to hundreds of
thousands of cancer patients across the world.
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Lantern Pharma Newsletter – The Spark: Sign-up here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
drug discovery and ADC programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug or ADC candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug and ADC
candidates and our plans to discover and develop drug and ADC
candidates and to maximize their commercial potential by advancing
such candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2022,
filed with the Securities and Exchange Commission on March 20,
2023. You may access our Annual Report on Form 10-K for the year
ended December 31, 2022 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005298/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
과거 데이터 주식 차트
부터 3월(3) 2025 으로 4월(4) 2025
Lantern Pharma (NASDAQ:LTRN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 4월(4) 2025
